Major drug companies continually research and develop new medications and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through lung cancer clinical trials, researchers test the effects of new drugs on a group of volunteers with lung cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug to treat lung cancer, its safety, and any possible side effects.
Some patients with lung cancer are reluctant to take part in clinical trials for fear of getting no treatment at all for their lung cancer. This is simply not true. Patients with lung cancer who participate in lung cancer clinical trials receive the most effective therapy currently available for the lung cancer -- or they may receive lung cancer treatments that are being evaluated for future use. These lung cancer drugs may be even more effective than the current lung cancer treatment. The only way to determine if a newer treatment is better than the currently available treatment is by clinical trial participation.
Based on the Surveillance, Epidemiology, and End Registry, the estimated incidence of stage IIIB NSCLC is 17.6%. The anticipated 5-year survival for the vast majority of patients who present with clinical stage IIIB NSCLC is 3% to 7%. In small case series, selected patients with T4, N0-1 disease, solely as the result of satellite tumor nodule(s) within the primary lobe, have been reported to have 5-year survival rates of 20%.[3,4][Level of evidence: 3iiiA]
Standard Treatment Options for...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.